New research suggests the viral vector purification market will attain a compound annual growth rate of 14.2 percent between 2021 and 2028.
List view / Grid view
IDT Biologika and Oncotec Pharma Produktion announce vaccine and oncology capacity expansion projects
21 October 2013 | By IDT Biologika
IDT Biologika GmbH, a major developer of pharmaceutical technology and a producer of proprietary and third-party biopharmaceuticals and viral and bacterial vaccines, and Oncotec Pharma Produktion announced investments dedicated to increasing their respective production capacities.